, Volume 24, Issue 7, pp 421-426
Date: 17 Sep 2012

Hypersensitivity to Nadroparin Calcium

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
The use of heparin to prevent or treat venous and pulmonary thrombosis, unstable angina and non-ST-elevation myocardial infarction is widely accepted. Nowadays, for many of these indications the unfractionated heparins (UFH; molecular weight [MW] 3–30 kDa) are largely being replaced by low-molecular-weight heparins (LMWHs; MW ≤5 kDa) because of the improved pharmacokinetic and pharmacodynamic properties as well as a better safety profile of the latter.[13] Adverse reactions to heparins include haemorrhages, osteopenia and immune-mediated hypersensitivity reactions, e.g. heparin-induced thrombocytopenia without and with (fatal) thrombosis,[410] immediate hypersensitivity reactions such as rhinoconjunctivitis,[11] asthma,[12] urticaria, angio-oedema and anaphylaxis,[1225] and delayed cutaneous reactions generally manifesting as infiltrated, eczematous plaques or leukocytoclastic vasculitis (type III Arthus reaction) at injection sites.[2635]

1. Case Report

A 47-year-old man with severe...